Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/50091
Title: Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS
Authors: Naranjo Hernández, Antonio 
Ojeda-Bruno, Soledad
Saavedra, Aida
Molina, Amparo
Negrín Hernández, Miguel Ángel 
UNESCO Clasification: 32 Ciencias médicas
321315 Traumatología
Keywords: Fracture
Osteoporosis
Cost
Treatment
Pharmaceutical expenditure
Issue Date: 2019
Journal: Expert Review of Pharmacoeconomics and Outcomes Research 
Abstract: Introduction: Fracture Liaison Service (FLS) model for secondary prevention of fractures has demonstrated its cost-effectiveness using decision models. We analyze the impact of a FLS on pharmaceutical expenditures for osteoporosis (OP) in real-world circumstances. Methods: Expenditures on OP medications from January 2011 to January 2017 were compiled. Pharmaceutical expenditures in the southern area of Gran Canaria were used as a control group to measure the impact of implementing an FLS in the northern area. We estimated generalized least squares regressions with interrupted time-series analysis where two interventions were considered: March 2012 (implementation of the FLS) and March 2016 (incorporation of nursing staff for inpatients with hip fracture). Results: The northern area incurred greater expenditures for group I and II drugs. The difference in bisphosphonates expenditures between areas varied from 10.5% higher in the northern area pre-FLS to 11.2% post-FLS and 18.3% since March 2016. However, interrupted time series models do not find a significant impact of implementation of FLS on the pharmaceutical expenditures for either drug group. Conclusion: The implantation of an FLS did not lead to an increase in pharmaceutical expenditures for OP over the 5-year period compared to the standard care provided for secondary fracture preventions.
URI: http://hdl.handle.net/10553/50091
ISSN: 1473-7167
DOI: 10.1080/14737167.2018.1513791
Source: Expert Review of Pharmacoeconomics and Outcomes Research [ISSN 1473-7167], v. 19 (1), p. 81-87
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

2
checked on Dec 4, 2022

Page view(s)

66
checked on Apr 23, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.